HALO * logo

Halozyme Therapeutics BMV:HALO * Stock Report

Last Price

Mex$680.00

Market Cap

Mex$88.8b

7D

0%

1Y

0.04%

Updated

20 Dec, 2023

Data

Company Financials +

Halozyme Therapeutics, Inc.

BMV:HALO * Stock Report

Market Cap: Mex$88.8b

HALO * Stock Overview

A biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. More details

HALO * fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance3/6
Financial Health3/6
Dividends0/6

Halozyme Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Halozyme Therapeutics
Historical stock prices
Current Share PriceUS$680.00
52 Week HighUS$680.00
52 Week LowUS$680.00
Beta1.25
11 Month Change0%
3 Month Changen/a
1 Year Change0.038%
33 Year Changen/a
5 Year Changen/a
Change since IPO-19.23%

Recent News & Updates

Recent updates

Shareholder Returns

HALO *MX BiotechsMX Market
7D0%0%0%
1Y0.04%0%0%

Return vs Industry: HALO * exceeded the MX Biotechs industry which returned -1.3% over the past year.

Return vs Market: HALO * underperformed the MX Market which returned 9.1% over the past year.

Price Volatility

Is HALO *'s price volatile compared to industry and market?
HALO * volatility
HALO * Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: HALO * has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine HALO *'s volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998393Helen Torleyhalozyme.com

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product.

Halozyme Therapeutics, Inc. Fundamentals Summary

How do Halozyme Therapeutics's earnings and revenue compare to its market cap?
HALO * fundamental statistics
Market capMex$88.79b
Earnings (TTM)Mex$4.33b
Revenue (TTM)Mex$13.33b

20.5x

P/E Ratio

6.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HALO * income statement (TTM)
RevenueUS$780.71m
Cost of RevenueUS$259.78m
Gross ProfitUS$520.93m
Other ExpensesUS$267.03m
EarningsUS$253.91m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)1.92
Gross Margin66.73%
Net Profit Margin32.52%
Debt/Equity Ratio601.0%

How did HALO * perform over the long term?

See historical performance and comparison